EGFR-IN-210
EGFR-IN-210 is a EGFR kinase inhibitor with an IC50 of 0.198 μM. EGFR-IN-210 induces antiproliferative, pro-apoptotic, G0/G1 cell cycle arrest, DNA synthesis inhibition and anti-migratory effects in cancer cells. EGFR-IN-210 can be used for the research of various cancers including colorectal cancer.
For research use only. We do not sell to patients.
- Formula: C30H24ClN7O3S2
- Molecular Weight:630.14
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
EGFR-IN-210 (Compound T6) exhibits broad-spectrum antiproliferative activity in the NCI-60 cell panel, with an average growth inhibition rate exceeding 100% across 5 cancer subtypes and a maximum inhibition rate of up to 200% in individual sensitive cell lines[1].
EGFR-IN-210 (0.53 μM; 48 h) potently inhibits the migration of HT29 colon cancer cells, reducing the wound healing rate to 16.85% within 48 h[1].
EGFR-IN-210 (0.53 μM; 1-3 weeks) potently inhibits the long-term proliferation and colony-forming abilities of HT29 colorectal cancer cells[1].
EGFR-IN-210 (0.53 μM; 24 h) induces G0/G1 cell cycle arrest in HT29 colorectal cancer cells, reduces the proportion of S-phase cells, while maintaining G2/M-phase cell levels comparable to those of the untreated control group[1].
EGFR-IN-210 (0.53 μM; 24 h) induces significant apoptosis in HT29 colorectal cancer cells, with a total apoptosis rate of 67.40%, and this process is mainly mediated via the late apoptosis pathway[1].
EGFR-IN-210 (48 h) exhibits favorable in vitro safety profiles, with low cytotoxicity against normal WI-38 human lung fibroblasts (IC50: 156.59 μM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HT29 colorectal cancer cells
-
Concentration:0.53 μM (IC50 concentration)
-
Incubation Time:48 h
-
Result:Potently inhibited HT29 colorectal cancer cell migration, reducing wound closure to 16.85% over 48 h.
-
Cell Line:HT29 colorectal cancer cells
-
Concentration:0.53 μM (IC50 concentration)
-
Incubation Time:24 h
-
Result:Induced G0/G1 cell cycle arrest, with 84.56% of cells in G0/G1 phase, 12.95% in S phase, and 1.97% in G2/M phase, compared to 82.58% (G0/G1), 15.45% (S), and 1.97% (G2/M) in untreated controls.
-
Cell Line:HT29 colorectal cancer cells
-
Concentration:0.53 μM (IC50 concentration)
-
Incubation Time:24 h
-
Result:Increased total apoptosis to 67.40%, consisting of 5.67% early apoptosis and 61.73% late apoptosis, compared to 30.16% total apoptosis (9.76% early, 20.40% late) in untreated controls.
Increased necrosis to 19.82%, compared to 3.89% in controls.
Chemical Information
-
Molecular Weight 630.14
-
Formula C30H24ClN7O3S2
-
SMILES
O=C1N(CC2=CC=CC=C2)C(SCC3=CN(CC(NC4=NC=C(C5=CC=C(OC)C=C5)S4)=O)N=N3)=NC6=CC(Cl)=CC=C61
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)